Comparison of AngioJet Rheolytic Thrombectomy Before Direct Infarct Artery Stenting With Direct Stenting Alone in Patients With Acute Myocardial Infarction The JETSTENT Trial

Careggi Hospital, Florence, Italy.
Journal of the American College of Cardiology (Impact Factor: 15.34). 10/2010; 56(16):1298-306. DOI: 10.1016/j.jacc.2010.06.011
Source: PubMed

ABSTRACT The aim of this study was to determine whether rheolytic thrombectomy (RT) before direct infarct artery stenting as compared with direct stenting (DS) alone results in improved myocardial reperfusion and clinical outcome in patients with acute myocardial infarction.
The routine removal of thrombus before infarct artery stenting is still a matter of debate.
This is a multicenter, international, randomized, 2-arm, prospective study. Eligible patients were patients with acute myocardial infarction, angiographic evidence of thrombus grade 3 to 5, and a reference vessel diameter ≥2.5 mm. Coprimary end points were early ST-segment resolution and (99m)Tc-sestamibi infarct size. An α value = 0.05 achieved by both coprimary surrogate end points or an α value = 0.025 for a single primary surrogate end point would be considered evidence of statistical significance. Other surrogate end points were Thrombolysis In Myocardial Infarction (TIMI) flow grade 3, corrected TIMI frame count, and TIMI grade 3 blush. Clinical end points were a composite of major adverse cardiovascular events at 1, 6, and 12 months.
From December 2005 to September 2009, 501 patients were randomly allocated to RT before DS or to DS alone. The ST-segment resolution was more frequent in the RT arm as compared with the DS alone arm: 85.8% and 78.8%, respectively (p = 0.043), while no difference between groups were revealed in the other surrogate end points. The 6-month major adverse cardiovascular events rate was 11.2% in the thrombectomy arm and 19.4% in the DS alone arm (p = 0.011). The 1-year event-free survival rates were 85.2 ± 2.3% for the RT arm, and 75.0 ± 3.1% for the DS alone arm (p = 0.009).
Although the primary efficacy end points were not met, the results of this study support the use of RT before infarct artery stenting in patients with acute myocardial infarction and evidence of coronary thrombus. (AngioJet Rheolytic Thrombectomy Before Direct Infarct Artery Stenting in Patients Undergoing Primary PCI for Acute Myocardial Infarction [JETSTENT]; NCT00275990).


Available from: Alfredo E Rodríguez, Apr 25, 2015
1 Follower
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The ESC is not responsible in the event of any contradiction, discrepancy and/or ambiguity between the ESC Guidelines and any other official recommendations or guidelines issued by the relevant public health authorities, in particular in relation to good use of healthcare or therapeutic strategies. Health professionals are encouraged to take the ESC Guidelines fully into account when exercising their clinical judgment as well as in the determination and the implementation of preventive, diagnostic or therapeutic medical strategies; however, the ESC Guidelines do not in any way whatsoever override the individual responsibility of health professionals to make appropriate and accurate decisions in consideration of each patient's health condition and, where appropriate and/or necessary, in consultation with that patient and the patient's care provider. Nor do the ESC Guidelines exempt health professionals from giving full and careful consideration to the relevant official, updated recommendations or guidelines issued by the competent public health authorities, in order to manage each patient's case in light of the scientifically accepted data pursuant to their respective ethical and professional obligations. It is also the health professional's responsibility to verify the applicable rules and regulations relating to drugs and medical devices at the time of prescription.
    Kardiologia polska 08/2014; 72(12):1253-379. DOI:10.5603/KP.2014.0224 · 0.52 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Reperfusion of myocardial tissue is the main goal of primary percutaneous coronary intervention (PPCI) with stent implantation in the treatment of acute ST-segment elevation myocardial infarction (STEMI). Although PPCI has contributed to a dramatic reduction in cardiovascular mortality over three decades, normal myocardial perfusion is not restored in approximately one-third of these patients. Several mechanisms may contribute to myocardial reperfusion failure, in particular distal embolization of the thrombus and plaque fragments. In fact, this is a possible complication during PPCI, resulting in microvascular obstruction and no-reflow phenomenon. The presence of a visible thrombus at the time of PPCI in patients with STEMI is associated with poor procedural and clinical outcomes. Aspiration thrombectomy during PPCI has been proposed to prevent embolization in order to improve these outcomes. In fact, the most recent guidelines suggest the routine use of manual aspiration thrombectomy during PPCI (class IIa) to reduce the risk of distal embolization. Even though numerous international studies have been reported, there are conflicting results on the clinical impact of aspiration thrombectomy during PPCI. In particular, data on long-term clinical outcomes are still inconsistent. In this review, we have carefully analyzed literature data on thrombectomy during PPCI, taking into account the most recent studies and meta-analyses.
    World Journal of Cardiology (WJC) 09/2014; 6(9):924-928. DOI:10.4330/wjc.v6.i9.924 · 2.06 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The major challenge in the treatment of ST-elevation myocardial infarction (STEMI) is not only restoration of normal coronary blood flow but also microvascular perfusion. In fact, both electrocardiographic (ST segment resolution) and angiographic measures of myocardial perfusion (myocardial blush grade) have been shown to predict mortality after primary percutaneous coronary intervention (PPCI). Initial enthusiasm for manual thrombectomy arose after the apparent mortality benefit observed in the TAPAS trial (N=1,071). Meta-analyses of small trials suggest that manual thrombectomy improves epicardial and microvascular perfusion with trends towards benefit for survival. On the other hand, meta-analyses of small trials of mechanical thrombectomy show improvement in ST resolution without an effect on survival. Recently, the TASTE trial (N=7,244) showed no reduction in mortality with manual thrombectomy but trends toward reduction in rates of rehospitalisation for recurrent MI and stent thrombosis. The interpretation of TASTE should be cautious given that the trial had a much lower than expected mortality, and modest but important treatment effects cannot be excluded (20-30%). The largest trial, the ongoing TOTAL trial (N=10,700), will help determine the effect of manual thrombectomy for important clinical outcomes. A planned individual patient meta-analysis of the TOTAL and TASTE trials will have approximately 17,000 patients to examine the effect on clinical outcomes.
    EuroIntervention: journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology 08/2014; 10(T):T35-T38. DOI:10.4244/EIJV10STA7 · 3.76 Impact Factor